Showing 1 - 3 results of 3 for search 'R van Vollenhoven', query time: 0.02s Refine Results
  1. 1
    S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

    S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, pl... by S Banerjee, S Singhal, V Shah, R Van Vollenhoven, M Pike, E Morand, I Catlett, VP Werth, JT Merrill, N Delev, C Hobar, B Sharkey, T Wegman

    Published 2022-10-01
    Article
  2. 2
    PO.8.186 SLE-T2T – a digital treat-to-target clinical decision support system for the management of systemic lupus erythematosus patients: development and usability evaluation

    PO.8.186 SLE-T2T – a digital treat-to-target clinical decision support system for the management of systemic lupus erythematosus patients: development and usability evaluation by R Van Vollenhoven, M Tsang-A-Sjoe, A Voskuyl, A Parra Sanchez, MG Grimberg, MMA Hanssen, MO Aben, EE Jairth, PS Dhoeme, JH Leopold

    Published 2022-10-01
    Article
  3. 3
    New EULAR guidelines about treatment systemic lupus eritematosus

    New EULAR guidelines about treatment systemic lupus eritematosus by G Bertsias, J Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I Gilboe, F Houssiau, T Huizinga, D Isenberg, C Kallenberg, M Khamashtau, J Piette, M Schneider, J Smolen, G Sturfelt, A Tincani, R van Vollenhoven, C Gordon, D Boumpas

    Published 2008-02-01
    Get full text
    Article

Search Tools: